Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crizanlizumab - Novartis

Next Previous
Drug Profile

Crizanlizumab - Novartis

Alternative Names: Adakveo; Crizanlizumab-tmca - Novartis; Ryverna; SEG-101; Sel G1

Latest Information Update: 29 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Selexys Pharmaceuticals
  • Developer Novartis
  • Class Antivirals; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Vaso-occlusive crisis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Vaso-occlusive crisis
  • Phase II Priapism; Vascular disorders
  • Phase I/II Myelofibrosis

Most Recent Events

  • 07 Aug 2025 Novartis terminates the phase I/II ADORE trial in Myelofibrosis (Combination therapy) in Australia, Spain, Belgium, Canada, Denmark, Hungary, Israel, Italy, Japan, South Korea, Netherlands, Romania, Russia, Sweden, Switzerland, Turkey, United Kingdom and Germany (PO), due to sponsor decision (NCT04097821)
  • 06 Jul 2025 Phase-II clinical trials in Vaso-occlusive-crisis (In children) (IV), Prior to July 2025 (Novartis pipeline, July 2025)
  • 07 Dec 2024 Updated efficacy and adverse event data from the phase II SOLACE-KIDS trial in Sickle cell disease presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top